WFH/X
Jul 29, 2025, 13:12
AAV Gene Therapies for Hemophilia A and B: Current Perspectives
The World Federation of Haemophilia (WFH) shared a proud post on X:
“Gene Therapy is transforming Hemophilia care. A new review highlights how AAV-based treatments for hemophilia A and B are delivering long-term results—some lasting years with just one dose. Challenges remain, but the future is promising.
Read more.”
Title: Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Authors: Roland W. Herzog, Radoslaw Kaczmarek, Katherine A. High
Stay informed with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis